Search for: "NOVARTIS PHARMACEUTICALS, CORPORATION"
Results 1 - 20 of 65
Sorted by Relevance | Sort by
Date
25 Nov, 2007 11:04 am
... Novartis Pharmaceuticals Corp., No. 06-6280 (JBS), 2007 WL 1521138 (D.N.J. May 22, 2007), so we're here to spread the word. ...
court. The statutory language, however, reaches further than that situation, as Thomson v. Novartis shows. In Thomson -- you guessed it --
Georgia plaintiffs sued defendants from Delaware, New ... And the plaintiffs seemingly made good faith efforts to serve the complaint on Novartis Pharmaceuticals Corporation. Plaintiffs tried to serve the company on December 22, 26, 27, 28, ...
2 Mar, 2007 9:06 am
At the March 6 annual meeting of Swiss pharmaceutical giant Novartis, chairman and CEO Daniel Vasella and Hans-Joerg Rudloff, chair of
the compensation committee, are up for reelection. Last week, the Ethos Foundation ... . However, the company has not disclosed what would constitute "annual pay" for purposes of
applying the multiple. Yola Biedermann, head of corporate governance at Ethos, told Governance Weekly that "it is clearly not just base compensation. In a worse case scenario,
the golden ...
16 Oct, 2006 7:58 pm
... to include the new lawsuits. New lawsuits filed: Biovail Laboratories filed a new lawsuit against Andrx Pharmaceuticals over Andrx's attempt to market generic Cardizem.
Novartis sued Par Pharmaceuticals, the third and most recent company to file an ANDA for generic Lotrel. Schering-Plough ... Order
dismissing the suit did not mention the case against Andrx. Source: Impax press release. Solvay Pharmaceuticals settled patent litigation with generic drug makers Par
Pharmaceutical Cos ...
15 Oct, 2008 8:38 am
... the FOIAs, AAJ uncovered the cozy relationship between federal officials and the industries they regulate. For example, the pharmaceutical industry intensified its efforts to
influence the FDA in the months leading up to the physician labeling rule's release on January ... AstraZeneca, Cephalon, Millenium, Eisai, Amgen, Astellas, GlaxoSmithKline, Bristol
Myers Squibb, Johnson & Johnson, Novartis, Merck, and 3M. Less than six months after this meeting, the agency would release its final
physician ...
2 Apr, 2007 11:46 pm
... produced from at least two sputtering deposits, based upon claim construction Teva Pharmaceuticals USA, Inc. v. Novartis
Pharmaceuticals Corporation, et al. (03/30/2007): appeal of dismissal of declaratory judgment action because ... action for patent
non-infringement or invalidity; discussion of five circumstances contributing to Teva's justiciable controversy is Novartis' pending
infringement litigation; reversal of district court's decision to dismiss the declaratory judgment action because "Teva ...
3 Apr, 2007 2:55 pm
... Outweigh Benefits Of Zelnorm (Posted by Tom Lamb at DrugInjuryWatch.com) On March 30, 2007 the FDA announced that Novartis
Pharmaceuticals Corporation had suspended the marketing and sales of Zelnorm (tegaserod), a widely prescribed medication for irritable
bowel ... population, said Dr. Stephen Cunningham, head of clinical development and medical affairs in the United States at Novartis. The
company reported its finding to the drug agency on Feb. 22. The agency mobilized a team of reviewers. The ...
11 Feb, 2008 9:20 am
February 2008 Australian Report Links Liver Failure And Hepatitis To Popular Novartis Drug (Posted by Tom Lamb at DrugInjuryWatch.com) A
February 4, 2008 article, "Anti-fungal tablet linked to liver deaths", ... liver reactions after taking a popular prescription drug used to treat fungal infections, Lamisil
(terbinafine), which is made by Novartis Pharmaceuticals Corporation (NVS). We get an overview
of this Australian regulatory report from the February 4 Herald Sun article: The Therapeutic Goods ...
21 Oct, 2007 12:55 pm
... chronic constipation in individuals under 65 years of age. On March 30, 2007, the FDA requested that Novartis Pharmaceuticals
Corporation ("Novartis"), the manufacturer of Zelnorm, voluntarily remove the drug from the market.
The recall is based on findings of an increased risk of heart attacks and strokes associated with the drug from clinical trials recently reported by Novartis. Novartis reported to the FDA the results of a new analysis of 29 short term randomized, controlled
clinical trials ...
21 Oct, 2007 5:37 pm
... a.m. HYMAN & ARMSTRONG, P.S.C., ET AL. V. GUNDERSON, ET AL. (2006-SC-175-DG) AND SANDOZ PHARMACEUTICALS CORPORATION, N/K/A
NOVARTIS PHARMACEUTICALS CORPORATION V. GUNDERSON, ET AL. (2006-SC-179-DG) "Medical ...
Intermediary Rule. Punitive Damages. In medical malpractice/products liability action against the doctor who prescribed, and the pharmaceutical company which manufactured, drug
administered to suppress postpartum lactation, among the numerous questions raised are issues ...
2 Dec, 2008 3:19 am
HYMAN & ARMSTRONG, P.S.C., ET AL. V. RONALD GUNDERSON (ADMINISTRATOR OF THE ESTATE OF MARY MARGARET GUNDERSON) ET AL. AND SANDOZ PHARMACEUTICALS CORPORATION (N/K/A NOVARTIS PHARMACEUTICALS CORPORATION) V. RONALD
GUNDERSON (ADMINISTRATOR OF THE ESTATE OF MARY MARGARET GUNDERSON) ET AL. ORDER MODIFIED THE OPINION OF THE COURT BY JUSTICE SCHRODER, RENDERED APRIL 24, 2008, BY SUBSTITUTION OF NEW
OPINION. 2006-SC-000175-DG 2006-SC-000179-DG
21 Nov, 2006 12:04 pm
... case involving a eczema remedy whose side effects included cancer. The case is Perry v. Novartis Pharmaceuticals Corporation, No. 05-CV-5350, and was filed in the U.S. District Court for the Eastern District of Pennsylvania. The Perry case also caught my attention
because I'm researching ... in 1996. The FDA pre-emption claim in Perry is narrower and, according to the plaintiffs' memorandum of law submitted in opposition to Novartis's motion to dismiss, rests on shaky legal ground.
18 Apr, 2008 3:10 pm
From the Supreme Court of Alabama: Ex parte Novartis Pharmaceuticals Corporation, In re:
Alabama Medicaid Pharmaceutical Average Wholesale Price Litigation White Sands Group, L.L.C., Valentine, and Rolison v. PRS II, LLC, et al. Chris Myers Pontiac-GMC, Inc., d/b/a
Chris Myers Automotive v. Perot Ex parte Nationwide Insurance Company, In re: Alexander v. Herron et al. From the Alabama Court of Civil Appeals: Roberts v. University of Alabama ...
10 Apr, 2007 1:49 pm
"The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased
risk of serious cardiovascular adverse events (heart problems)...
19 Aug, 2007 5:13 pm
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic
monitoring. Novartis Pharmaceuticals Corporation et al. v. Ranbaxy Inc. et al.3:07-cv-03755;
filed August 9, 2007 in the District of Court...
18 Feb 12:47 pm
Sales representatives of Novartis Pharmaceutical Corporation who brought a class action have
been determined to be exempt employees under the Fair Labor Standards Act, thus bringing an abrupt end (for the plaintiffs) to the litigation. Federal district court Judge Paul Crotty,
sitting in the Southern District of New York, has ruled that these employees were "outside salespersons" and exempt under that provision. Then (although it did not have to reach the
issue ...
16 Nov 4:51 am
... ) The Coinco strategy - what can go wrong with ownership of patents within a corporate enterprise Mars, Inc v Coin Acceptors; Novartis Pharmaceuticals v Teva Pharmaceuticals (Property, intangible) The audacity of the USPTO - PTO Deputy Director speech ( ... trademark:
Topline Corp v Rocky Brands Wholesale LLC (Seattle Trademark Lawyer) Trump University - General Patent Corporation secures settlement and
agreement from Trump University regarding 'Negotiate to Win' service mark owned by Common Ground ...
16 Nov 4:51 am
... ) The Coinco strategy - what can go wrong with ownership of patents within a corporate enterprise Mars, Inc v Coin Acceptors; Novartis Pharmaceuticals v Teva Pharmaceuticals (Property, intangible) The audacity of the USPTO - PTO Deputy Director speech ( ... trademark:
Topline Corp v Rocky Brands Wholesale LLC (Seattle Trademark Lawyer) Trump University - General Patent Corporation secures settlement and
agreement from Trump University regarding 'Negotiate to Win' service mark owned by Common Ground ...
30 Aug 10:00 pm
... Aug. 10, 2009). There, Bivins ingested Elidel and claims to have suffered an injury. Bivins (a citizen of Texas) sued Novartis
Pharmaceuticals (a Delaware corporation with its principal place of business in New Jersey), Novartis Pharma GmbH (a ... not removable if a party "joined and served" as a defendant is a "citizen of the State in which such action is brought."
Novartis thus removed the action before plaintiff had served the resident defendant with the complaint. Although courts have split on ...
6 Aug 6:50 am
... Burks v. Abbott Laboratories, ___ F. Supp.2d ___, 2009 WL 2246740, at *7 (D. Minn. July 24, 2009); Frey v. Novartis ... WL 2246740, at *8
(D. Minn. July 24, 2009); Frey v. Novartis Pharmaceuticals Corp., 2009 WL 2230471, at *7 (S.D. Ohio July ... 23, 2009) (failure to
specify violation). Gross Negligence Sykes v. Bayer Pharmaceuticals Corp., 548 F. Supp.2d 208, 217 (E.D. Va ... WL 362437, at *8 (N.D. Tex. Feb. 13, 2009) (piercing
corporate veil); Sprouse v. American Tire Distributors, Inc., 2009 WL 111601 ...
14 Aug 1:04 am
... Burks v. Abbott Laboratories, ___ F. Supp.2d ___, 2009 WL 2246740, at *7 (D. Minn. July 24, 2009); Frey v. Novartis ... WL 2246740, at *8
(D. Minn. July 24, 2009); Frey v. Novartis Pharmaceuticals Corp., 2009 WL 2230471, at *7 (S.D. Ohio July ... 23, 2009) (failure to
specify violation). Gross Negligence Sykes v. Bayer Pharmaceuticals Corp., 548 F. Supp.2d 208, 217 (E.D. Va ... WL 362437, at *8 (N.D. Tex. Feb. 13, 2009) (piercing
corporate veil); Sprouse v. American Tire Distributors, Inc., 2009 WL 111601 ...
Search on: Blawgs.FM | BlawgSearch Google
Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!